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ABSTRACT
Introduction: The
SARS-CoV-2
pandemic
necessitated better understanding of the impact
of disease-modifying therapies on COVID-19
outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination
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contains supplementary material available at https://
doi.org/10.1007/s40120-022-00341-z.

status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients.
Methods: COVID-19 data analyzed were from
the ongoing, open-label, long-term extension
phase 3b ALITHIOS study from December 2019
(pandemic start) and post-marketing cases from
August 2020 (ofatumumab first approval) up to
25 September 2021. COVID-19 cases, severity,
seriousness, outcomes, vaccination status, and
breakthrough infection were evaluated.
Results: As of 25 September 2021, 245 of 1703
patients (14.4%) enrolled in ALITHIOS receiving ofatumumab (median exposure: 2.45 years)
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reported COVID-19 (confirmed: 210; suspected:
35). Most COVID-19 was of mild (44.1%) or
moderate (46.5%) severity, but 9% had severe/
life-threatening COVID-19. There were 24 serious cases (9.8%) with 23 patients hospitalized;
22 recovered and 2 died. At study cut-off, 241
patients (98.4%) had recovered or were recovering or had recovered with sequelae and 2
(0.8%) had not recovered. Ofatumumab was
temporarily interrupted in 39 (15.9%) patients.
Before COVID-19 onset, IgG levels were within
the normal range in all COVID-19–affected
patients, while IgM was \ 0.4 g/l in 23 (9.4%)
patients. No patient had a reinfection. Overall,
559 patients were vaccinated (full, 476; partial,
74; unspecified, 9). Breakthrough infection was
reported in 1.5% (7/476) patients, and 11
reported COVID-19 after partial vaccination. As
of 25 September 2021, the Novartis Safety
Database (* 4713 patient-treatment years)
recorded 90 confirmed COVID-19 cases receiving ofatumumab. Most cases were non-serious
(n = 80), and ten were serious (1 medically significant, 9 hospitalized, 0 deaths). Among 36 of
90 cases with outcomes reported, 30 recovered
and 6 did not recover.
Conclusion: COVID-19 in RMS patients on
ofatumumab was primarily of mild/moderate
severity and non-serious in these observational
data. Most recovered from COVID-19 without
treatment interruption. Two people died with
COVID-19. Breakthrough COVID-19 despite
being
fully/partially
vaccinated
was
uncommon.
Keywords: ALITHIOS; Anti-CD20 therapy; Bcell therapy; COVID-19; Ofatumumab; Postmarketing; Relapsing multiple sclerosis; SARSCoV-2; Vaccination

Key Summary Points
Why carry out this study?
With the growing knowledge about
COVID-19 and the launch of COVID-19
vaccinations, more evidence from clinical
studies and real-world settings is needed
to understand the impact of COVID-19
and vaccination status in multiple
sclerosis (MS) patients receiving diseasemodifying therapies, especially
B-cell–depleting therapies.
We analyzed the characteristics of COVID19 cases, outcomes, vaccination status,
and breakthrough infections of relapsing
MS (RMS) patients receiving ofatumumab
in the open-label long-term phase 3b
ALITHIOS study and Novartis postmarketing safety database as of September
25, 2021.
What was learned from the study?
Most COVID-19 cases in MS patients
treated with ofatumumab were mild or
moderate in severity and characterized as
non-serious.
A small proportion of patients had
COVID-19 despite being fully or partially
vaccinated, from which all recovered.
These observational data provide relevant
information to help healthcare
professionals better understand the
severity and outcomes of COVID-19 in
patients with RMS receiving ofatumumab,
a B-cell–depleting therapy.

INTRODUCTION
The global pandemic outbreak of coronavirus
disease (COVID-19) impacted the well-being of
both healthy individuals and people with
underlying health conditions [1]. More than
231 million people worldwide have been
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infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in
more than 4.7 million deaths (2.1%) as of
September 25, 2021, the data cut-off for the
current study. As of January 17, 2022, 326 million cases and 5.5 million deaths worldwide
have been reported [2]. Vaccine breakthrough
COVID-19 constitutes a small percentage (up
to 1.5%) of all fully vaccinated cases [3, 4] but is
expected to rise as COVID-19 vaccine effectiveness is waning over time and new SARS-CoV-2
variants emerge.
People with multiple sclerosis (MS) are at an
increased risk of serious infections due to concomitant comorbidities or immunosuppressive
treatments [5–8]. A recently published pooled
analysis reported a 24% increased risk of death
from COVID-19 in patients with MS after age
standardization as compared with the general
population [9]. The hospitalization rate reported due to COVID-19 in people with MS (general/with or without disease modifying therapy
[DMT]) varied between 15.5% to 36.5% and the
mortality rate from 1.97% to 10.3% [1, 9–13].
Several publications suggest that there is no
increased risk of contracting COVID-19 in people with MS compared with the general population [13]. However, several factors such as
older age, presence of comorbidities, elevated
body mass index (BMI), MS-related disability,
progressive MS phenotype, type and duration of
DMT, and recent corticosteroid treatment may
affect the severity and outcome of COVID-19 in
patients with MS [1, 9, 10, 14, 15].
Anti-CD20 monoclonal antibodies (mAbs)
deplete B cells, an action that may compromise
immune responses and lead to a higher risk of
severe COVID-19 [16]. Opinions were published
during the COVID-19 pandemic recommending
delayed dosing for B-cell–depleting therapies
based on a perception of increased risk of
COVID-19 [14, 17, 18]. In addition, some studies have observed that B-cell therapies impact
humoral responses to COVID-19 vaccination
[19–21]. Although much was learned since the
start of the pandemic, healthcare professionals
(HCPs) continue to face uncertainties in the
management of patients with MS in routine
clinical practice and are concerned with
potential reinfections, waning effect of
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vaccination, and vaccine breakthrough infections. More evidence from clinical studies and
post-marketing settings regarding the impact of
COVID-19 in people with MS treated with
B-cell–depleting therapies is needed [13].
Ofatumumab is a fully human anti-CD20
mAb that induces B-cell depletion and is
approved for the treatment of relapsing MS
(RMS). Ofatumumab received marketing
authorization in the US on August 20, 2020,
which was in the midst of the COVID-19 pandemic—declared by the World Health Organization (WHO) on March 11, 2020 [22]. The
present analyses aimed to describe the characteristics of COVID-19 cases, COVID-19 vaccination status, and breakthrough infections in
people with RMS receiving ofatumumab in the
ongoing open-label ALITHIOS study and from
post-marketing reports reported spontaneously
to the Novartis Global Safety Database.

METHODS
Open-Label Extension Study
Data Collection
ALITHIOS (NCT03650114) is an ongoing, openlabel, single-arm, long-term extension phase 3b
study designed to assess the safety, tolerability,
and effectiveness of ofatumumab 20 mg
administered subcutaneously every 4 weeks for
up to 5 years in people with RMS [23, 24]. The
study enrolled patients from the APLIOS [25]
(NCT03560739),
APOLITOS
[26]
(NCT03249714), and ASCLEPIOS I/II [27]
(NCT02792218/NCT02792231) phase 2 and 3
trials who were treated with ofatumumab in the
core studies and continued with the same
treatment and patients who received teriflunomide in the core and switched to ofatumumab
in the extension study. Data from ofatumumabtreated ALITHIOS patients and their reported
COVID-19 status from December 2019 to
September 25, 2021 (data cut-off) were
analyzed.
COVID-19 Diagnosis
Cases were considered as confirmed COVID-19
if there was a positive laboratory test result
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including real-time polymerase chain reaction,
antigen detection, or serological evidence of
infection, as reported by the investigator. Cases
were considered as suspected COVID-19 in the
absence of a positive SARS-CoV-2 laboratory test
result but with signs and symptoms consistent
with COVID-19 (Fig. S1).
Study Outcomes and Assessments
Demographics, key baseline disease characteristics and history were summarized for patients
who entered the ALITHIOS study, for patients
with confirmed/suspected COVID-19, and for
hospitalized COVID-19 patients. A Wilcoxon
rank sum test was also performed between
hospitalized and non-hospitalized MS patients
for selected potential risk factors including age
and BMI. Exposure to ofatumumab was expressed as the individual’s time at risk, which was
defined as time from the first dose of ofatumumab until 100 days after the last dose of
ofatumumab.
COVID-19 cases, seriousness and severity
category, COVID-19 outcomes, reinfections,
COVID-19 vaccination status, and vaccine
breakthrough infection with associated outcomes were assessed. COVID-19 seriousness
category was based on the regulatory reporting
definition established by the International
Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human
Use (ICH) [28] guidelines E2A [29]. Severity
assessment was provided by the reporting
investigator based on the National Cancer
Institute’s Common Terminology Criteria for
Adverse Events (CTCAE [v5.0]) grading system
[30], as described in the protocol; adverse events
(AEs) were reported as mild (Grade 1), moderate
(Grade 2), severe (Grade 3), or life-threatening
(Grade 4). COVID-19 outcomes were reported
by the investigator as recovered or recovering or
recovered with sequelae, not recovered, or fatal
(Fig. S1). Per the Centers for Disease Control
and Prevention, reinfection was defined as a
second confirmed infection after 90 days from
the end date of the recovered first COVID-19.
Vaccine breakthrough COVID-19 was defined as
confirmed COVID-19 after being fully vaccinated. Fully vaccinated means at least 14 days
after receiving all recommended doses of a

COVID-19 vaccine (excluding booster), and
partially vaccinated means either not received
all recommended doses or it was \ 14 days after
receiving all recommended doses of a COVID19 vaccine [31].
The last assessed serum immunoglobulin
(IgG and IgM) levels before COVID-19 onset
and in relation to COVID-19 seriousness were
evaluated. For serious COVID-19 cases, age,
BMI, Expanded Disability Status Scale (EDSS),
and other potential risk factors were collected.
Additional risk factor modeling analysis was not
performed for these data, which will be in scope
for future publications.
Ethics Statement
Ethics approval for the ALITHIOS study
(NCT03650114) was obtained from all ethics
committees or institutional review board at
each site and the study is in accordance with the
ethical code of the ethics committee or institutional review board for each study site and the
Declaration of Helsinki. After approval from the
ethics committee, written informed consent
was obtained from all subjects before commencing the trial-related procedures and
allowed the results to be part of a publication.
Post-marketing Reports
Data Collection
The analysis included post-marketing COVID19 cases in RMS patients from the Novartis
Global Safety Database received from the time
of ofatumumab’s first approval in August 2020
up to September 25, 2021. The database captures AEs reported to Novartis by HCPs,
patients, and other sources.
COVID-19 Diagnosis
COVID-19 cases were classified as confirmed if a
SARS-CoV-2–positive test result was available or
if the patient was reported to have been diagnosed with COVID-19. Cases without a positive
test result or a definitive diagnosis were classified as suspected (Fig. S1).
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Open-label ALITHIOS study

Post-marketing reports

Overall ALITHIOS patientsa
(N = 1703)

Total patient years
(Years = 4,713)

Patients with any COVID-19
(N = 245)

Patients with any COVID-19
(N = 93)

Confirmed
COVID-19
(N = 210)

Suspected
COVID-19
(N = 35)

Confirmed
COVID-19
(N = 90)

Serious cases
(n = 23)

Serious cases
(n = 1)

Serious cases
(n = 10)

Non-serious cases
(n = 187)

Non-serious cases
(n = 34)

Non-serious cases
(n = 80)

Suspected
COVID-19
(N = 3)

Fig. 1 Patient designation in the open-label ALITHIOS
study and post-marketing setting. a Patients in the openlabel ALITHIOS study (N = 1703) rolled-over from the

APOLITOS (n = 57), APLIOS (n = 279), and ASCLEPIOS I/II (n = 1367) studies

Outcomes and Assessments
Patient demographics, COVID-19 cases, severity, seriousness (including hospitalization),
outcomes, and COVID-19 vaccination status
were summarized based on reported information. Cases were considered ‘‘serious’’ based on
the ICH regulatory reporting definition. Severity assessment of COVID-19 cases was adjudicated independently by 2 experts (BJW and
BACC) using the US Food and Drug Administration and WHO COVID-19 severity scales
where data were available. Cases were classified
as asymptomatic, mild, moderate, severe, or
critical (Fig. S1).
If available, the outcome status of each
COVID-19–affected individual was reported as
recovered/recovering/recovered with sequelae,
condition unchanged, condition deteriorated,
or fatal.

ALITHIOS Long-Term Open-Label
Extension Study

RESULTS
As of September 25, 2021, COVID-19 was
reported in 245 patients with RMS receiving
ofatumumab in the long-term open-label
extension ALITHIOS study and 90 patients with
RMS in the post-marketing setting (Fig. 1).

As of the cut-off, 1703 people with RMS had
received at least one dose of ofatumumab in the
ALITHIOS study who were rolled over from
previously completed studies, namely, APOLITOS (n = 57), APLIOS (n = 279), and ASCLEPIOS
I/II (n = 1367). Demographics, baseline characteristics, and disease history of the patients who
reported any COVID-19–related AE were comparable with those of the overall ALITHIOS
population (Table 1).
COVID-19 Cases Clinical Severity, Seriousness,
and Reinfection
Of the 1703 patients, 245 (14.4%) had reported
a COVID-19–related AE, including 210 (85.7%)
confirmed COVID-19 cases and 35 (14.3%)
suspected COVID-19 cases (Fig. 1). Most
COVID-19 cases occurred in the timeframe of
October 2020 to January 2021 (Fig. 2). Among
all reported cases, the majority (90.6%) had
infection of mild (108 [44.1%]) or moderate
(114 [46.5%]) severity, while 19 had severe
(7.8%) and 3 had life-threatening (1.2%)
COVID-19; CTCAE grading was missing for 1
(0.4%) case. A total of 24 serious COVID-19
cases were reported; all but 1 patient were hospitalized, 2 patients required (non-invasive)
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Table 1 Patient demographics and disease characteristics in the open-label ALITHIOS study
OMB overall Any COVID–19 related AE
20 mg
Overall
Conﬁrmed
N = 1703a
COVID-19
COVID-19
n = 245
n = 210

Suspected
COVID-19
n = 35

Hospitalized overall
COVID-19
n = 23

38.6 ± 9.06

37.9 ± 8.75

38 ± 8.79

37.5 ± 8.58

41.7 ± 7.5

725 (42.6)

98 (40.0)

85 (40.5)

13 (37.1)

16 (69.6)

1186 (69.6)

171 (69.8)

147 (70.0)

24 (68.6)

13 (56.5)

White

1525 (89.5)

224 (91.4)

191 (91.0)

33 (94.3)

22 (95.7)

Asian

75 (4.4)

7 (2.9)

7 (3.3)

0

1 (4.3)

39 (2.3)

6 (2.4)

5 (2.4)

1 (2.9)

0

Russian Federation

386 (22.7)

71 (29.0)

60 (28.6)

11 (31.4)

7 (30.4)

US

275 (16.1)

36 (14.7)

29 (13.8)

7 (20.0)

3 (13.0)

Poland

213 (12.5)

35 (14.3)

30 (14.3)

5 (14.3)

5 (21.7)

Spain

117 (6.9)

18 (7.3)

15 (7.1)

3 (8.6)

3 (13.0)

Czech Republic

108 (6.3)

19 (7.8)

19 (9.0)

0

0

Overweight: BMI 25
to \ 30 kg/m2

427 (25.1)

62 (25.3)

52 (24.8)

10 (28.6)

9 (39.1)

Obese: BMI C 30 kg/m2

307 (18.0)

45 (18.4)

40 (19.0)

5 (14.3)

7 (30.4)

BMI (kg/m2), mean ± SD

25.42 ± 5.92 25.42 ± 5.941 25.49 ± 6.022

25 ± 5.489

27.32 ± 5.316

EDSS [ 3.5, n (%)

430 (25.2)

40 (19.0)

4 (11.4)

3 (13.0)

EDSS, mean ± SD

2.84 ± 1.381 2.63 ± 1.205

2.65 ± 1.226

2.49 ± 1.074

2.67 ± 1.104

RRMS

1621 (95.2)

239 (97.6)

204 (97.1)

35 (100)

22 (95.7)

SPMS

82 (4.8)

6 (2.4)

6 (2.9)

0

1 (4.3)

60 (3.5)

60 (24.5)

52 (24.8)

8 (22.9)

3 (13.0)

Cardiac disorders

9 (0.5)

9 (3.7)

8 (3.8)

1 (2.9)

0

Metabolism and nutrition
disorders

14 (0.8)

14 (5.7)

13 (6.2)

1 (2.9)

1 (4.3)

Respiratory, thoracic and
mediastinal disorders

28 (1.6)

28 (11.4)

25 (11.9)

3 (8.6)

1 (4.3)

Characteristics

Age (years), mean ± SD
Age [ 41 years, n (%)
Female, n (%)
Race, n (%)

Black or African American
b

Country , n (%)

BMI categories, n (%)

44 (18.0)

Type of MS, n (%)

Selected AEs prior to
COVID-19 onsetc, n (%)
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Table 1 continued
Characteristics

Vascular disorders

OMB overall
20 mg
N = 1703a

Any COVID–19 related AE
Overall
COVID-19
n = 245

Conﬁrmed
COVID-19
n = 210

Suspected
COVID-19
n = 35

Hospitalized overall
COVID-19
n = 23

18 (1.1)

18 (7.3)

15 (7.1)

3 (8.6)

2 (8.7)

For age, BMI, and EDSS, baseline was the value at or the last non-missing assessment prior to the ﬁrst dose of ofatumumab.
Type of MS was assessed at the screening of core studies. Cardiac disorders include tachycardia, angina pectoris, atrial
ﬁbrillation, bradycardia, nodal arrhythmia supraventricular extrasystoles, Wolff-Parkinson-White syndrome, and cardiomyopathy. Metabolism and nutrition disorders include hypertriglyceridemia, vitamin D deﬁciency, hyperglycemia,
hypercholesterolemia, iron deﬁciency, decreased appetite, diabetes mellitus, hypovitaminosis, and vitamin B complex deﬁciency. Respiratory, thoracic, and mediastinal disorders include cough, oropharyngeal pain, rhinitis allergic, nasal congestion,
asthma, bronchial hyperreactivity, catarrh, chronic obstructive pulmonary disease, dyspnea, nasal discomfort, pharyngeal
inﬂammation, respiratory disorder, rhinorrhea, and throat irritation. Vascular disorders include hypertension, hematoma,
extremity necrosis, orthostatic hypertension, peripheral venous disease, superﬁcial vein thrombosis, thrombophlebitis, and
hypertensive crisis
AE, adverse event; BMI, body mass index; COVID-19, coronavirus disease; EDSS, Expanded Disability Status Scale; MS,
multiple sclerosis; OMB, ofatumumab; RRMS, relapsing–remitting multiple sclerosis; SD, standard deviation; SPMS,
secondary progressive multiple sclerosis
a
N = 1703 represents the enrolled population in the ALITHIOS study
b
Overall COVID-19 rate of [ 5%
c
The selection of prior AEs was based on the following MedDRA System Organ Classes (SOCs) Cardiac disorders,’
‘Metabolism and nutrition disorders,’ ‘Respiratory, thoracic and mediastinal disorders,’ and ‘Vascular disorders’

mechanical ventilation, and 2 patients died. No
patient had reinfection.
Demographics and Disease Characteristics
of Overall and Hospitalized COVID-19 Cases
Patient demographics and disease characteristics of COVID-19 patients are summarized in
Table 1. COVID-19–affected patients had a
mean ± standard deviation (SD) age of
37.9 ± 8.75 years at first initiation of ofatumumab, while hospitalized (n = 23) patients
were older (41.7 ± 7.5 years; Wilcoxon ranksum text of hospitalized vs non-hospitalized
p = 0.026). Moreover, 69.8% of all COVID-19
patients were female, while 56.5% of hospitalized patients were female. The percentage of
patients who were overweight or obese
(BMI: C 25 kg/m2) was 43.7% among overall
COVID-19–affected patients and higher among
those hospitalized (69.6%; Wilcoxon rank-sum
text on BMI of hospitalized vs. non-hospitalized

p = 0.038). The mean EDSS at first dose of ofatumumab was comparable between COVID19–affected patients (2.63 ± 1.2) and those
hospitalized (2.67 ± 1.1). Overall, 24.5% of
patients with COVID-19 had relevant previously reported AEs prior to COVID-19 onset
compared to 13% of hospitalized patients.
The median (range) ofatumumab exposure
duration (expressed as ‘‘time at risk’’) of the 245
patients with COVID-19 was 2.45 [0.1–4.98]
years. The median onset time of COVID-19
since the first dose of ofatumumab was
2.08 years. Among COVID-19–affected patients,
ofatumumab treatment interruption was reported in 39 (15.9%) patients, none of whom permanently discontinued treatment, except for
two people who had a fatal COVID-19 outcome
(Table 2).
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Number of confirmed cases
per week (n)

COVID-19 cases worldwide from WHO dashboard
1st SARS-CoV-2 vaccines available
Dec-2020

6,000,000
5,000,000

1st case of Delta variant
Oct-2020a

4,000,000
3,000,000
2,000,000

WHO reports
cluster of cases
of pneumonia in
Wuhan, China
Dec-31-2019

WHO declared
global pandemic
Mar-11-2020

1,000,000
0
Dec-1-19

Mar-1-20

Jun-1-20

Sep-1-20

Dec-1-20

Mar-1-21

Jun-1-21

Sep-1-21
Data cutoff date
Sep-25-2021

COVID-19 cases in the ALITHIOS study (N=245)

Life-threatening

Severity grade

Severe

Moderate

Mild

Missingb
Dec-1-19

Mar-1-20

Jun-1-20

Sep-1-20

Dec-1-20
Partially Vaccinated

Mar-1-21

Jun-1-21

Fully Vaccinated

Sep-1-21

Unvaccinated/Unspecified

Fig. 2 COVID-19 cases over time in the open-label
ALITHIOS study by severity and vaccine status. aFirst case
of Omicron variant reported after data cut-off: November
24, 2021. bSeverity grade for one patient was not yet
reported at the time of data cut-off, as ALITHIOS is an

ongoing study, and the data are subject to change.
COVID-19, coronavirus disease; SARS-CoV-2, severe
acute respiratory syndrome coronavirus-2; WHO, World
Health Organization

COVID-19 Outcomes and Duration
At the time of data cut-off (Table 2), the
majority (241, 98.4%) of COVID-19 cases had
either recovered or recovered with sequelae, or
were recovering, while two (0.8%) had not yet
recovered, and two cases (0.8%) had a fatal
outcome (Fig. S2).
Of the 24 serious cases, 22 recovered and 2
were fatal. The first fatal COVID-19 case was a
female patient in her 5th decade of life from
Europe who was on ofatumumab for 3.7 years.
The patient was slightly overweight and had
experienced a MS relapse 2.5 months before the
onset of COVID-19, which was treated with
methylprednisolone 1 g intravenously daily for

4 days. Her latest reported EDSS was 3.5. The
patient was hospitalized with COVID-19 pneumonia and required prolonged mechanical
ventilation; 33 days after the start of COVID-19,
the patient died because of COVID-19 pneumonia. The second fatal COVID-19 case was a
male patient in his 4th decade of life from Asia
who was on ofatumumab treatment for
1.5 years. Reported comorbidities for this case
were diabetes and hypertension. This patient
was diagnosed with COVID-19 but was not
hospitalized. Ten days after the start of COVID19, the patient died because of COVID-19.
Neither of the fatal cases were vaccinated
against COVID-19; their serum IgG and IgM
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Table 2 Summary of COVID-19 cases in the open-label ALITHIOS study
Characteristics

Any COVID–19 related AE
Overall
COVID-19
N = 245

Conﬁrmed
COVID-19
n = 210

Suspected
COVID-19
n = 35

Hospitalized
overall
COVID-19
n = 23

Non-serious

221 (90.2)

187 (89.0)

34 (97.1)

0

Serious

24 (9.8)

23 (11.0)

1 (2.9)

23 (100)

Hospitalized

23 (9.4)

22 (10.5)

1 (2.9)

23 (100)

Mild

108 (44.1)

90 (42.9)

18 (51.4)

1 (4.3)

Moderate

114 (46.5)

99 (47.1)

15 (42.9)

5 (21.7)

Severe

19 (7.8)

17 (8.1)

2 (5.7)

14 (60.9)

Life-threatening

3 (1.2)

3 (1.4)

0

3 (13.0)

Missing CTCAE grading

1 (0.4)

1 (0.5)

0

0

Recovered/recovered with sequalae/recovering

241 (98.4)

206 (98.1)

35 (100)

22 (95.7)

Not recovered

2 (0.8)

2 (1.0)

0

0

Fatal

2 (0.8)

2 (1.0)

0

1a (4.3)

COVID-19 duration in days, median (range)

15 (1–216)

15 (1–216)

14 (3–47)

14 (4–57)

COVID-19 onset time since the ﬁrst dose of
ofatumumab, years, mean ± SD

2.32 ± 0.999 2.38 ± 1

1.91 ± 0.903

2.52 ± 0.86

AE led to ofatumumab interruption, n (%)

39 (15.9)

34 (16.2)

5 (14.3)

9 (39.1)

AE led to ofatumumab discontinuation, n (%)

2 (0.8)

2 (1.0)

0

1 (4.3)

COVID-19 seriousness, n (%)

COVID-19 maximum severity, n (%)

COVID-19 outcome, n (%)

COVID-19 duration could not be calculated for 2 patients because of missing AE end date. Please refer to supplementary
material (Fig. S1) for severity and seriousness deﬁnitions
AE adverse event; COVID-19 coronavirus disease; CTCAE Common Terminology Criteria for Adverse Events; SD
standard deviation
a
One patient with a fatal outcome was not admitted to the hospital owing to personal circumstances and ﬁnancial reasons

levels were within the normal range throughout
the study.
The overall median (range) COVID-19 disease duration was 15 (1 to 216) days in 243
patients with non-missing end date (Table 2).

Immunoglobulin Levels and Their Association
with COVID-19 Occurrence and Seriousness
Of the 245 COVID-19 cases, no COVID-19–affected participant had IgG levels below the
lower limit of normal (LLN; 5.65 g/l) before
COVID-19 onset. Twenty-three participants
(9.4%) (confirmed: n = 19; suspected: n = 4) had
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IgM levels below the LLN (0.4 g/l) before
COVID-19 onset, 22 of whom had non-serious
COVID-19, and one 56-year-old male patient
who was hospitalized with pneumonia and had
an IgM level of 0.34 g/l 3 months before his
diagnosis of COVID-19. The 22 non-serious
cases were of mild-to-moderate severity, and all
patients recovered with or without sequelae.
Low IgG/IgM levels were not associated with
any serious SARS-CoV-2 infections.
Vaccination Status, Vaccine Breakthrough
Infections, and Their Severity and Outcomes
In total, 559 ALITHIOS patients were vaccinated
of whom 476 were fully vaccinated (of these 27
patients received a booster vaccination), 74
were partially vaccinated, and 9 received an
unspecified COVID-19 vaccination (Table S1).
Among 550 fully or partially vaccinated
patients, messenger ribonucleic acid (mRNA)based vaccine (78.9%) was the most commonly
received, followed by viral-vector-based (nonreplicating) vaccine (16.9%; Fig. S3). Among
476 fully vaccinated patients, 7 (1.5%) had
breakthrough COVID-19, of which 5 were
mild/moderate or non-serious, 1 was severe,
and 1 was life-threatening, and all 7 patients
recovered. Among vaccinated patients, 11
(1.97%) had confirmed COVID-19 after partial
vaccination, of which 9 were mild/moderate or
non-serious and 2 were severe, and all 11
patients recovered. No cases of COVID-19 were
reported after COVID-19 booster vaccination as
per the data cut-off.
Post-marketing Setting
As of September 25, 2021, 90 confirmed and 3
suspected COVID-19 cases were reported to the
Novartis Safety Database from the post-marketing setting for patients with RMS on ofatumumab subcutaneous 20 mg dose (Fig. 1). The
cumulative post-marketing patient exposure
since the first launch of ofatumumab up to data
cut-off is estimated to be approximately 4713
patient-treatment years. The patient exposure
data are derived from sales data and are therefore estimates.
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COVID-19 Post-marketing Patient
Characteristics
For the 90 confirmed cases, information on age
was available for 62 patients, and the mean
(range) age was 45 (19–66) years; 60 patients
were female, 22 were male, and gender was not
reported for the remainder. Many of the postmarketing cases had limited information
regarding prior MS DMTs, comorbidities, MS
duration, time of exposure to ofatumumab,
EDSS/disability status, COVID-19 symptoms,
and outcome, and some patients were lost to
follow-up. All of the patients reported COVID19 from the US, with the exception of one from
France (diagnosed with neuromyelitis optica spectrum disorder and aquaporine?) [32].
COVID-19 Cases, Seriousness, Severity,
and Outcomes
Of the 90 confirmed cases (Table 3), 10 were
serious in nature, including 1 medically significant case and 9 hospitalizations. No fatalities or
life-threatening COVID-19 cases were reported
in the post-marketing setting.
Of the 90 confirmed COVID-19 cases, severity of COVID-19 was assessed as mild in 32
patients, moderate in 7 patients, severe in 3
patients, and critical in 1 patient by independent adjudication. In the remaining 47 cases,
severity could not be assessed because of the
insufficient information provided. Limited
information was provided for the 9 hospitalized
patients. Age was included in four of the nine
cases (29, 42, 60, and 64 years of age). There was
no information regarding comorbidities or MS
severity. Outcome was provided in one of the
nine cases, and the patient’s condition was
improving; outcome was not provided in the
remaining eight cases.
Thirty of the post-marketing patients on
ofatumumab with COVID-19 recovered or were
recovering, 6 patients had no change in condition at the time of the report, and outcomes
were not available for the remaining 54 patients
(Fig. S4).
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Table 3 Summary of conﬁrmed COVID-19 cases in the
post-marketing setting
Conﬁrmed
COVID-19
N = 90
Reporter type, n (%)
HCP

12 (13.3)

Non-HCP

78 (86.7)
a

COVID-19 seriousness , n (%)
Non-serious
Serious

b

80 (88.9)
10 (11.1)

Fatal

0

Hospitalization

9 (0.1)

Life-threatening

0

Medically signiﬁcant

1 (1.11)

COVID-19 maximum severityc, n
Mild

32

Moderate

7

Severe

3

Critical

1

COVID-19 worst outcome, n
Recovered/recovered with sequalae/ 30
recovering
Condition unchanged

6

Fatal

0

Not reported

54

Severity was assessed using the WHO and FDA guidelines
COVID-19 coronavirus disease; HCP healthcare professional; US FDA United States Food and Drug Administration; WHO World Health Organization
a
Percentages are calculated based on available information
for seriousness (N = 90)
b
No information regarding comorbidities was provided; in
the post-marketing setting serious cases are likely to be
reported more frequently than non-serious cases
c
Percentages are calculated based on available information
for severity (N = 90)

Vaccine Breakthrough Infections and Their
Severity and Outcomes
Limited information regarding vaccination status was available. There were four post-marketing cases in which patients developed COVID19 post-vaccination; however, with limited
information on vaccination dates, only one of
these cases can be determined as breakthrough
COVID-19 (recovered) while the other 3 (2 cases
with outcome unknown and 1 case with condition unchanged) are considered as COVID-19
post full/partial unspecified vaccination.

DISCUSSION
The data presented herein are reassuring in the
sense that most MS patients with COVID-19
reported in the open-label ALITHIOS study and
the post-marketing setting had non-serious
COVID-19 disease and the majority recovered
despite being treated with ofatumumab, which
depletes circulating B cells.
Of 245 patients recorded as COVID-19 cases
in ALITHIOS, fewer than 10% were serious or
resulted in hospitalization with only two
deaths. Fatal outcomes (2/245 or 0.8%) due to
COVID-19 in ofatumumab-treated patients
were lower than those reported in the general
population (2.1%) [2], overall MS general population (1.97%) [9], and MS patients with DMTs
(1.4–5.9%) [1, 11, 12] and without DMTs
(10.3%) [12]. The two ALITHIOS patients with a
fatal outcome were unvaccinated and had
underlying comorbidities of diabetes and
hypertension in one patient and slightly overweight (BMI of 28.3 kg/m2) in another patient,
which are known risk factors for severe COVID19 [33]. The hospitalization rate due to COVID19 observed in the ALITHIOS study (9.4%) was
also lower than that previously reported for the
general
MS
population
(15.5–20.9%)
[1, 9, 12, 13, 34] as well as in patients with MS
treated with DMTs (11.5–32.6%) [1, 10–12] and
without DMTs (16.2–42.9%) [10, 12, 13, 34].
The findings of clinical severity and outcomes
of COVID-19 cases in ofatumumab-treated
patients are consistent with COVID-19 data
presented previously with a data cut-off of January 29, 2021 [35]. The present data analysis
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does not suggest any evidence of an increased
risk of severe COVID-19 or fatal outcomes in MS
patients treated with ofatumumab compared
with the hospitalization and fatality rates as
reported in published literature for the general
and MS populations [9, 13].
These comparisons should not be over-interpreted. Several factors may contribute to
differences in the reported COVID-19 severity
and outcomes in different MS populations.
There may be relevant differences in the
prevalence of known risk factors such as older
age, type of MS, level of MS-related disability,
and use of different types of DMTs. In addition,
COVID-19 cases reported in MS registries are
subject to ascertainment bias and may be
skewed toward more severe cases being reported. It should be noted that the patients in
ALITHIOS rolled over from earlier clinical trials
that enrolled people up to 55 years of age and
excluded those with certain comorbid conditions [25–27]. Thus, they may not fully represent the real-world population of people with
MS.
In the recently published retrospective report
on the combined Italian and French registries of
confirmed COVID-19 in patients with MS,
worse COVID-19 outcomes in people with MS
on two other B-cell–depleting agents (ocrelizumab and rituximab) were noted compared
to other DMTs. Additionally, patients reported
in the registries taking rituximab did worse than
those treated with ocrelizumab, and the study
did not report on COVID-19 cases in patients
taking ofatumumab [33]. Worse outcomes on
rituximab versus ocrelizumab were also noted
in the North American COViMS Registry data
[10]. Salter and colleagues reported three cases
of COVID-19 in people taking ofatumumab,
with one hospitalization and no deaths. Sormani and colleagues hypothesized that the
worse outcomes in patients treated with rituximab compared with ocrelizumab were related
to longer exposure to the drug [33].
One concern with long-term B-cell depletion
is the potential reduction in Ig production.
Earlier studies found an increased risk of serious
infections in patients with low IgG levels taking
ocrelizumab [36]. In previously reported findings on the ALITHIOS trial [37] and the
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ASCLEPIOS I/II trials [38], no association
between infection and lower IgG/IgM levels was
observed in the overall RMS population treated
with ofatumumab for up to 3.5 years [37, 38]
and for up to 2 years [38], respectively. Consistent with previous findings, the present analysis
of data from the ALITHIOS trial showed no
apparent association between IgG/IgM levels
and COVID-19 occurrence or its severity or
outcome. Among all 245 COVID-19 cases in the
present analysis, all patients had IgG levels
above the LLN, while 23 had IgM below the
LLN. The mean IgG/IgM levels remained above
the LLN for up to 168 weeks in people with
COVID-19, although mean IgM levels declined
during this time, consistent with the mean IgM/
IgG trend in the overall ofatumumab safety
population (data not shown). Prior registry
studies have not reported data on IgG or IgM
levels [10, 33, 39].
Data on the humoral and T-cell responses to
COVID-19 in people taking ofatumumab are
scarce. In an independent assessment of IgG
antibodies during SARS-CoV-2 infection (funded by Novartis), four COVID-19 cases from the
ALITHIOS study were examined, all of whom
had mild COVID-19 and recovered. Three of the
four patients had normal levels of IgM and IgG
without measurable counts of CD19 cells prior
to COVID-19. One patient had ofatumumab
dosing temporarily interrupted because of low
IgM. None of the three patients without circulating B cells developed detectable antibodies to
SARS-CoV-2 [40]. Conversely, all three patients
tested for SARS-CoV-2 had T-cell responses
detected by interferon-c ELISpot assay. Further
investigation of both humoral and T-cell
responses in a larger cohort of ofatumumabtreated patients contracting COVID-19 is
warranted.
The Novartis Safety Database might be more
representative of real-world experience of people living with RMS. As of September 25, 2021,
90 confirmed COVID-19 post-marketing cases
on ofatumumab had been reported in the
Novartis Safety Database. This is a voluntary
post-marketing database, and all but one case
came from the US, making the data potentially
subject to bias. Similar to the results from ALITHIOS, most of the confirmed COVID-19 cases
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were considered non-serious in nature except
ten serious COVID-19 cases, including nine
patients who were hospitalized. No fatal or lifethreatening cases were reported. It has been
suggested that in a general post-marketing setting, serious cases are reported more frequently
than non-serious cases [41].
Limitations
ALITHIOS is an open-label, single-arm, Phase 3b
extension study. The inherent design of study
lacks a control group. The relatively small
number of patients in the hospitalized subgroup
may hamper the risk factor and subgroup
analyses.
The post-marketing surveillance includes the
relatively small number of reported COVID-19
cases, which likely reflects the limited overall
post-marketing exposure to ofatumumab, as it
received marketing authorization in August
2020. Moreover, reporting of post-marketing
cases is voluntary or spontaneous in nature, and
a large proportion of cases had incomplete data
or incomplete follow-up. The post-marketing
setting also includes literature reports of AEs,
but cases gleaned from the scientific literature
are typically delayed in acquisition. Therefore,
interpretation of these post-marketing reports
should be made with caution. Although both
the ALITHIOS clinical trial and post-marketing
surveillance did not capture information on the
SARS-CoV-2 variants causing COVID-19 in the
ofatumumab-treated patients, most cases were
likely caused by either the alpha or delta variant
as these variants were the most dominant variants up to the data cut-off of September 25,
2021.
To date (December 2021), this is one of the
largest studies in patients with RMS treated with
a B-cell depleting therapy to report on COVID19 cases post-vaccination. A small number of
vaccinated patients in the ALITHIOS study and
post-marketing setting reported breakthrough
infections of which most cases were of mild-tomoderate severity and had a non-serious nature;
all recovered. The immunization response to
COVID-19 vaccinations is complex involving
an interplay of both cellular and humoral
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immunity [42], both of which could be
impaired because of B-cell depletion [19–21]
Studies that further evaluate immunization
responses to COVID-19 vaccination in patients
on ofatumumab therapy are in progress.
A COVID-19 vaccination sub-study embedded
in the ALITHIOS open-label extension is
underway to investigate the effect of ofatumumab on humoral and T-cell responses following selected COVID-19 vaccines. In
addition, three phase 4 studies are underway to
evaluate the immune response to the COVID-19
mRNA vaccine, two being conducted in the US
(clinicaltrials.gov
NCT04878211
and
NCT04847596) and one in Germany (clinicaltrials.gov NCT04869358).
Evidence-based guidelines for treatment
decisions for MS in the current COVID-19 pandemic are starting to emerge. However, much of
the current guidelines continue to derive from
expert opinions. At this point, treatment should
be tailored in consideration of the individual
patient’s history, existing comorbid conditions,
and severity of MS [1, 14]. Initiation or continuation of ofatumumab treatment should be
decided based on the benefit-risk assessment of
each individual.

CONCLUSIONS
The current study included comprehensive data
from the ongoing open-label extension study
(ALITHIOS) and post-marketing reports of ofatumumab-treated RMS patients with confirmed
or suspected COVID-19. These observational
data were reassuring in that most COVID-19
cases were mild or moderate in severity and
most patients recovered from COVID-19 despite
being on ofatumumab, a B-cell-depleting therapy. Two fatal cases of COVID-19 were reported
in ALITHIOS. There were no cases of reinfection, and a small proportion of patients had
COVID-19 despite being fully or partially vaccinated, from which all patients recovered.
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